XPOMET Event Podcast
Taros’ CEO invited to speak on the exclusive Podcast of the XPOMET© Medicinale in Berlin, 10 – 12 Oct 2019
Dortmund, September 2019 ++++
As modern medicine becomes increasingly complex and data-driven, traditional healthcare is being transformed into a dynamic, multi-layered and highly connected global ecosystem. In that sense the XPOMET© Medicinale inspires with the latest developments in healthcare, bringing together professionals and decision makers to discuss new collaborative models and products. As a serial biotech entrepreneur and co-leader of the collaborative innovation drug discovery platform European Lead Factory (ELF), Taros’ CEO Dr. Dimitrios Tzalis has been invited to the few selected speakers to contribute his expert opinion to the high level discussion on pioneering medicines, open innovation and future directions in drug discovery.
In the light of Dimitrios’ presenation at the XPOMET© Medicinale, he was invited to give a pre-talk about his opinion on the transformation of the drug discovery process and his activities to contribute to that ambitious mission. Please follow the link to listen the exclusive XPOMET podcast with Dimitrios.
About Taros Chemicals
Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at| taros.de
As a leading contract research organization in discovery chemistry and custom synthesis, Taros provides comprehensive solutions to meet our clients’ needs from diverse branches and applications
Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations, despite challenges, bridging very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project, starting from the development of synthetic routes to…